25 XP   0   0   10

Genmab AS
Buy, Hold or Sell?

Let's analyse Genmab together

PenkeI guess you are interested in Genmab AS. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Genmab AS. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Genmab AS

I send you an email if I find something interesting about Genmab AS.

Quick analysis of Genmab (30 sec.)










What can you expect buying and holding a share of Genmab? (30 sec.)

How much money do you get?

How much money do you get?
$0.03
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$6.94
Expected worth in 1 year
$7.85
How sure are you?
95.0%

+ What do you gain per year?

Total Gains per Share
$0.95
Return On Investment
3.3%

For what price can you sell your share?

Current Price per Share
$28.97
Expected price per share
$26.19 - $31.88
How sure are you?
50%

1. Valuation of Genmab (5 min.)




Live pricePrice per Share (EOD)

$28.97

Intrinsic Value Per Share

$8.66 - $38.18

Total Value Per Share

$15.60 - $45.12

2. Growth of Genmab (5 min.)




Is Genmab growing?

Current yearPrevious yearGrowGrow %
How rich?$4.5b$3.6b$620m14.6%

How much money is Genmab making?

Current yearPrevious yearGrowGrow %
Making money$155.3m$197.1m-$41.7m-26.9%
Net Profit Margin24.7%39.0%--

How much money comes from the company's main activities?

3. Financial Health of Genmab (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#17 / 1009

Most Revenue
#31 / 1009

Most Profit
#22 / 1009

Most Efficient
#64 / 1009

What can you expect buying and holding a share of Genmab? (5 min.)

Welcome investor! Genmab's management wants to use your money to grow the business. In return you get a share of Genmab.

What can you expect buying and holding a share of Genmab?

First you should know what it really means to hold a share of Genmab. And how you can make/lose money.

Speculation

The Price per Share of Genmab is $28.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genmab.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genmab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.94. Based on the TTM, the Book Value Change Per Share is $0.23 per quarter. Based on the YOY, the Book Value Change Per Share is $0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genmab.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.140.5%0.301.0%0.301.0%0.230.8%0.140.5%
Usd Book Value Change Per Share0.110.4%0.230.8%0.291.0%0.260.9%0.170.6%
Usd Dividend Per Share0.000.0%0.010.0%0.010.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.110.4%0.240.8%0.311.1%0.260.9%0.170.6%
Usd Price Per Share31.84-35.72-35.80-32.69-45.55-
Price to Earnings Ratio56.67-34.79-51.68-74.99--191.94-
Price-to-Total Gains Ratio291.33--80.32-201.30-227.41-1,021.00-
Price to Book Ratio4.59-5.53-6.52-7.58-37.08-
Price-to-Total Gains Ratio291.33--80.32-201.30-227.41-1,021.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share28.97
Number of shares34
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.230.26
Usd Total Gains Per Share0.240.26
Gains per Quarter (34 shares)8.048.94
Gains per Year (34 shares)32.1535.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11312213526
22625417062
339386210698
441241182141134
551561503176170
661871823211206
772182144246242
882492464282278
992802785317314
10103113106352350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%37.03.00.092.5%40.020.00.066.7%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%38.02.00.095.0%44.013.03.073.3%
Dividend per Share3.00.01.075.0%5.00.07.041.7%5.00.015.025.0%5.00.035.012.5%5.00.055.08.3%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%38.02.00.095.0%44.013.03.073.3%

Fundamentals of Genmab

About Genmab AS

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Fundamental data was last updated by Penke on 2024-04-11 10:00:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Genmab AS.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genmab earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • A Net Profit Margin of 13.7% means that $0.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genmab AS:

  • The MRQ is 13.7%. The company is making a huge profit. +2
  • The TTM is 24.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ13.7%TTM24.7%-11.0%
TTM24.7%YOY39.0%-14.3%
TTM24.7%5Y34.1%-9.4%
5Y34.1%10Y40.1%-6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.7%-200.1%+213.8%
TTM24.7%-216.8%+241.5%
YOY39.0%-288.3%+327.3%
5Y34.1%-449.1%+483.2%
10Y40.1%-605.5%+645.6%
1.1.2. Return on Assets

Shows how efficient Genmab is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • 1.8% Return on Assets means that Genmab generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genmab AS:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM3.2%-1.4%
TTM3.2%YOY4.8%-1.6%
TTM3.2%5Y4.2%-1.0%
5Y4.2%10Y4.4%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%-13.3%+15.1%
TTM3.2%-12.8%+16.0%
YOY4.8%-11.7%+16.5%
5Y4.2%-13.9%+18.1%
10Y4.4%-15.7%+20.1%
1.1.3. Return on Equity

Shows how efficient Genmab is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • 2.0% Return on Equity means Genmab generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genmab AS:

  • The MRQ is 2.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.0%TTM3.6%-1.6%
TTM3.6%YOY5.4%-1.8%
TTM3.6%5Y4.7%-1.1%
5Y4.7%10Y5.0%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%-16.9%+18.9%
TTM3.6%-16.1%+19.7%
YOY5.4%-15.1%+20.5%
5Y4.7%-19.3%+24.0%
10Y5.0%-20.2%+25.2%

1.2. Operating Efficiency of Genmab AS.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genmab is operating .

  • Measures how much profit Genmab makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • An Operating Margin of 35.7% means the company generated $0.36  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genmab AS:

  • The MRQ is 35.7%. The company is operating very efficient. +2
  • The TTM is 30.7%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ35.7%TTM30.7%+5.0%
TTM30.7%YOY43.1%-12.3%
TTM30.7%5Y33.3%-2.6%
5Y33.3%10Y39.4%-6.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ35.7%-296.2%+331.9%
TTM30.7%-232.5%+263.2%
YOY43.1%-298.2%+341.3%
5Y33.3%-492.1%+525.4%
10Y39.4%-632.4%+671.8%
1.2.2. Operating Ratio

Measures how efficient Genmab is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.64 means that the operating costs are $0.64 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Genmab AS:

  • The MRQ is 0.643. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.693. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.643TTM0.693-0.050
TTM0.693YOY0.595+0.098
TTM0.6935Y0.634+0.059
5Y0.63410Y0.589+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6433.231-2.588
TTM0.6933.310-2.617
YOY0.5953.890-3.295
5Y0.6345.739-5.105
10Y0.5897.876-7.287

1.3. Liquidity of Genmab AS.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genmab is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.34 means the company has $13.34 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Genmab AS:

  • The MRQ is 13.341. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.522. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.341TTM13.522-0.181
TTM13.522YOY13.901-0.379
TTM13.5225Y14.231-0.709
5Y14.23110Y12.576+1.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.3413.890+9.451
TTM13.5224.173+9.349
YOY13.9015.344+8.557
5Y14.2316.126+8.105
10Y12.5766.448+6.128
1.3.2. Quick Ratio

Measures if Genmab is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • A Quick Ratio of 18.66 means the company can pay off $18.66 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genmab AS:

  • The MRQ is 18.659. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 19.306. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ18.659TTM19.306-0.646
TTM19.306YOY20.284-0.978
TTM19.3065Y21.316-2.011
5Y21.31610Y20.259+1.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.6593.514+15.145
TTM19.3063.998+15.308
YOY20.2845.380+14.904
5Y21.3166.105+15.211
10Y20.2596.404+13.855

1.4. Solvency of Genmab AS.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genmab assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genmab to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Genmab assets are financed with 10.4% credit (debt) and the remaining percentage (100% - 10.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genmab AS:

  • The MRQ is 0.104. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.107. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.104TTM0.107-0.003
TTM0.107YOY0.106+0.001
TTM0.1075Y0.098+0.009
5Y0.09810Y0.118-0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1040.339-0.235
TTM0.1070.336-0.229
YOY0.1060.271-0.165
5Y0.0980.366-0.268
10Y0.1180.389-0.271
1.4.2. Debt to Equity Ratio

Measures if Genmab is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genmab to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.6% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genmab AS:

  • The MRQ is 0.116. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.120. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.120-0.003
TTM0.120YOY0.118+0.001
TTM0.1205Y0.110+0.010
5Y0.11010Y0.145-0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1160.388-0.272
TTM0.1200.402-0.282
YOY0.1180.335-0.217
5Y0.1100.426-0.316
10Y0.1450.461-0.316

2. Market Valuation of Genmab AS

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Genmab generates.

  • Above 15 is considered overpriced but always compare Genmab to the Biotechnology industry mean.
  • A PE ratio of 56.67 means the investor is paying $56.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genmab AS:

  • The EOD is 51.564. Based on the earnings, the company is expensive. -2
  • The MRQ is 56.673. Based on the earnings, the company is expensive. -2
  • The TTM is 34.788. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD51.564MRQ56.673-5.108
MRQ56.673TTM34.788+21.885
TTM34.788YOY51.679-16.892
TTM34.7885Y74.986-40.199
5Y74.98610Y-191.943+266.929
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD51.564-2.264+53.828
MRQ56.673-2.629+59.302
TTM34.788-2.680+37.468
YOY51.679-4.145+55.824
5Y74.986-6.257+81.243
10Y-191.943-6.254-185.689
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Genmab AS:

  • The EOD is 20.561. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 22.598. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 47.166. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD20.561MRQ22.598-2.037
MRQ22.598TTM47.166-24.568
TTM47.166YOY77.059-29.893
TTM47.1665Y63.326-16.160
5Y63.32610Y250.579-187.253
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.561-2.973+23.534
MRQ22.598-3.333+25.931
TTM47.166-3.553+50.719
YOY77.059-5.605+82.664
5Y63.326-8.376+71.702
10Y250.579-8.865+259.444
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genmab is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.59 means the investor is paying $4.59 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Genmab AS:

  • The EOD is 4.176. Based on the equity, the company is fair priced.
  • The MRQ is 4.590. Based on the equity, the company is fair priced.
  • The TTM is 5.527. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.176MRQ4.590-0.414
MRQ4.590TTM5.527-0.937
TTM5.527YOY6.522-0.995
TTM5.5275Y7.582-2.055
5Y7.58210Y37.077-29.495
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.1761.896+2.280
MRQ4.5902.115+2.475
TTM5.5272.093+3.434
YOY6.5222.884+3.638
5Y7.5823.542+4.040
10Y37.0773.916+33.161
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Genmab AS.

3.1. Institutions holding Genmab AS

Institutions are holding 7.222% of the shares of Genmab AS.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31AllianceBernstein L.P.2.39110.191315614510609930164.1005
2023-12-31BlackRock Inc0.67520.00364409575-407844-8.466
2023-12-31Capital Research & Mgmt Co - Division 30.62140.02914057922-260420-6.0306
2023-12-31Harding Loevner L.P.0.50380.54733289895856652.6735
2023-12-31Wellington Management Company LLP0.36280.01412369331-56050-2.311
2023-12-31Renaissance Technologies Corp0.22890.0737149480032080027.3254
2023-12-31First Trust Advisors L.P.0.19450.0441127009517529216.0113
2023-12-31Morgan Stanley - Brokerage Accounts0.16680.00311089097-11422-1.0379
2023-12-31Goldman Sachs Group Inc0.16170.003105584841951465.9267
2023-12-31Envestnet Asset Management Inc0.14180.01229259188465301066.3198
2023-12-31Bank of America Corp0.13620.0029889164-23123-2.5346
2023-12-31Stifel Financial Corp0.1030.027672893-35216-4.9732
2023-12-31Royal Bank of Canada0.09820.0048640989-194821-23.3092
2023-12-31Wells Fargo & Co0.08530.0046557132-32261-5.4736
2023-12-31Northern Trust Corp0.08250.0031539030-20014-3.58
2023-12-31Millennium Management LLC0.07840.0071512281371068262.7718
2023-12-31Hardman Johnston Global Advisors LLC0.07390.4934482657-109661-18.5139
2023-12-31American Century Companies Inc0.06990.0145642259141.3127
2023-09-30Point72 Asset Management, L.P.0.04270.028727860110110156.9583
2023-12-31FMR Inc0.0410.0007267505-154932-36.6758
Total 6.25911.503840873665+7119421+17.4%

3.2. Funds holding Genmab AS

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31AllianceBernstein US L/C Growth Eqty MF0.72860.52784746311703361.5042
2024-02-29AB Large Cap Growth A0.70320.481945809361291492.9011
2024-03-28iShares Biotechnology ETF0.6481.65454221059-7353-0.1739
2023-12-31Vanguard Health Care Inv0.35090.1568228585500
2023-09-30Delaware Ivy Mid Cap Growth A0.30351.2642197673100
2024-02-29AB American Growth AX USD0.21140.5094137705900
2024-02-29American Growth One D0.21140.5094137705900
2024-03-31First Trust NYSE Arca Biotech ETF0.18773.1233122270500
2024-02-29AB US Large Cap Growth CT B0.17090.48291113525283602.6134
2024-03-31AB Large Cap Growth (MA)0.06140.713539969400
2024-02-29AB Growth A0.05620.7014365820-98490-21.2121
2023-12-19Nomura ACI AdvMed Impact Inv MF0.0531.0178345244-32756-8.6656
2024-01-31SAST SA AB Growth 10.05040.516932847111630.3553
2023-12-31Alliance US Large Cap Growth Equity CIT0.05020.600232730812181259.2771
2024-02-29BlackRock Health Sciences Opps Inv A0.04440.094828940500
2024-01-31International Biotechnology Ord0.03722.031624238511508590.4046
2023-09-30Delaware Ivy VIP Mid Cap Growth II0.02511.277516357400
2024-02-29AB VPS Large Cap Growth A0.02260.4811470677810.5339
2023-12-31LVIP Blended Large Cap Gr Mgd Vol Std0.02190.28051428735368060.1841
2023-12-31Baron International Growth Strategy0.02130.863913894500
Total 3.959317.289325792026+381767+1.5%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Genmab AS compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1090.229-52%0.294-63%0.259-58%0.170-36%
Book Value Per Share--6.9376.511+7%5.504+26%4.543+53%2.744+153%
Current Ratio--13.34113.522-1%13.901-4%14.231-6%12.576+6%
Debt To Asset Ratio--0.1040.107-2%0.106-1%0.098+6%0.118-12%
Debt To Equity Ratio--0.1160.120-3%0.118-2%0.110+6%0.145-20%
Dividend Per Share---0.008-100%0.013-100%0.004-100%0.002-100%
Eps--0.1400.301-53%0.299-53%0.228-38%0.135+4%
Free Cash Flow Per Share--0.3520.384-8%0.195+81%0.217+62%0.123+188%
Free Cash Flow To Equity Per Share--0.3470.351-1%0.152+128%0.238+46%0.144+142%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--38.178--------
Intrinsic Value_10Y_min--8.663--------
Intrinsic Value_1Y_max--1.338--------
Intrinsic Value_1Y_min--0.558--------
Intrinsic Value_3Y_max--5.916--------
Intrinsic Value_3Y_min--1.955--------
Intrinsic Value_5Y_max--12.780--------
Intrinsic Value_5Y_min--3.646--------
Market Cap18850257076.480-10%20717714370.56023242360468.480-11%23513936414.890-12%21415489381.540-3%29712831545.343-30%
Net Profit Margin--0.1370.247-45%0.390-65%0.341-60%0.401-66%
Operating Margin--0.3570.307+16%0.431-17%0.333+7%0.394-9%
Operating Ratio--0.6430.693-7%0.595+8%0.634+1%0.589+9%
Pb Ratio4.176-10%4.5905.527-17%6.522-30%7.582-39%37.077-88%
Pe Ratio51.564-10%56.67334.788+63%51.679+10%74.986-24%-191.943+439%
Price Per Share28.970-10%31.84035.720-11%35.795-11%32.692-3%45.554-30%
Price To Free Cash Flow Ratio20.561-10%22.59847.166-52%77.059-71%63.326-64%250.579-91%
Price To Total Gains Ratio265.069-10%291.329-80.324+128%201.302+45%227.411+28%1021.003-71%
Quick Ratio--18.65919.306-3%20.284-8%21.316-12%20.259-8%
Return On Assets--0.0180.032-44%0.048-62%0.042-57%0.044-59%
Return On Equity--0.0200.036-44%0.054-62%0.047-57%0.050-59%
Total Gains Per Share--0.1090.236-54%0.307-64%0.263-58%0.172-36%
Usd Book Value--4513908000.0004236411900.000+7%3616374300.000+25%2974790336.280+52%1794610986.210+152%
Usd Book Value Change Per Share--0.1090.229-52%0.294-63%0.259-58%0.170-36%
Usd Book Value Per Share--6.9376.511+7%5.504+26%4.543+53%2.744+153%
Usd Dividend Per Share---0.008-100%0.013-100%0.004-100%0.002-100%
Usd Eps--0.1400.301-53%0.299-53%0.228-38%0.135+4%
Usd Free Cash Flow--229194000.000250042800.000-8%128341500.000+79%142200240.000+61%80259958.170+186%
Usd Free Cash Flow Per Share--0.3520.384-8%0.195+81%0.217+62%0.123+188%
Usd Free Cash Flow To Equity Per Share--0.3470.351-1%0.152+128%0.238+46%0.144+142%
Usd Market Cap18850257076.480-10%20717714370.56023242360468.480-11%23513936414.890-12%21415489381.540-3%29712831545.343-30%
Usd Price Per Share28.970-10%31.84035.720-11%35.795-11%32.692-3%45.554-30%
Usd Profit--91392000.000155366400.000-41%197135400.000-54%141414840.000-35%87941866.320+4%
Usd Revenue--668018400.000588121800.000+14%521041500.000+28%392899920.000+70%229258691.970+191%
Usd Total Gains Per Share--0.1090.236-54%0.307-64%0.263-58%0.172-36%
 EOD+4 -4MRQTTM+12 -23YOY+15 -205Y+15 -2010Y+18 -17

4.2. Fundamental Score

Let's check the fundamental score of Genmab AS based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1551.564
Price to Book Ratio (EOD)Between0-14.176
Net Profit Margin (MRQ)Greater than00.137
Operating Margin (MRQ)Greater than00.357
Quick Ratio (MRQ)Greater than118.659
Current Ratio (MRQ)Greater than113.341
Debt to Asset Ratio (MRQ)Less than10.104
Debt to Equity Ratio (MRQ)Less than10.116
Return on Equity (MRQ)Greater than0.150.020
Return on Assets (MRQ)Greater than0.050.018
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Genmab AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.860
Ma 20Greater thanMa 5029.627
Ma 50Greater thanMa 10029.339
Ma 100Greater thanMa 20029.874
OpenGreater thanClose28.850
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in DKK. All numbers in thousands.

Summary
Total Assets35,289,000
Total Liabilities3,679,000
Total Stockholder Equity31,610,000
 As reported
Total Liabilities 3,679,000
Total Stockholder Equity+ 31,610,000
Total Assets = 35,289,000

Assets

Total Assets35,289,000
Total Current Assets33,139,000
Long-term Assets2,150,000
Total Current Assets
Cash And Cash Equivalents 14,867,000
Short-term Investments 13,268,000
Net Receivables 4,947,000
Inventory 57,000
Total Current Assets  (as reported)33,139,000
Total Current Assets  (calculated)33,139,000
+/-0
Long-term Assets
Property Plant Equipment 1,641,000
Long Term Investments 134,000
Long-term Assets  (as reported)2,150,000
Long-term Assets  (calculated)1,775,000
+/- 375,000

Liabilities & Shareholders' Equity

Total Current Liabilities2,484,000
Long-term Liabilities1,195,000
Total Stockholder Equity31,610,000
Total Current Liabilities
Short-term Debt 90,000
Accounts payable 2,307,000
Other Current Liabilities 54,000
Total Current Liabilities  (as reported)2,484,000
Total Current Liabilities  (calculated)2,451,000
+/- 33,000
Long-term Liabilities
Capital Lease Obligations 770,000
Long-term Liabilities  (as reported)1,195,000
Long-term Liabilities  (calculated)770,000
+/- 425,000
Total Stockholder Equity
Common Stock66,000
Retained Earnings 19,023,000
Accumulated Other Comprehensive Income 60,000
Other Stockholders Equity 12,461,000
Total Stockholder Equity (as reported)31,610,000
Total Stockholder Equity (calculated)31,610,000
+/-0
Other
Capital Stock66,000
Cash and Short Term Investments 28,135,000
Common Stock Shares Outstanding 66,152
Current Deferred Revenue33,000
Liabilities and Stockholders Equity 35,289,000
Net Debt -14,097,000
Net Invested Capital 31,610,000
Net Working Capital 30,655,000
Property Plant and Equipment Gross 2,317,000
Short Long Term Debt Total 770,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
2,221,534
2,081,365
1,954,929
2,458,246
2,481,601
2,202,563
2,052,818
1,672,901
1,564,432
1,459,576
1,417,866
1,772,128
1,692,886
1,754,706
1,675,996
1,797,023
1,731,527
2,791,482
2,717,904
2,830,889
2,866,681
3,175,247
3,283,766
3,501,141
3,902,548
3,911,133
4,128,273
4,353,053
5,238,236
5,405,594
6,028,515
5,895,194
6,602,942
6,783,115
7,199,663
7,403,733
8,460,999
8,734,717
8,977,313
13,330,303
15,144,000
15,303,000
20,683,000
21,522,000
21,143,000
22,210,000
22,483,000
23,985,000
24,627,000
24,914,000
27,476,000
30,686,000
30,278,000
30,394,000
31,978,000
35,238,000
35,289,000
35,289,00035,238,00031,978,00030,394,00030,278,00030,686,00027,476,00024,914,00024,627,00023,985,00022,483,00022,210,00021,143,00021,522,00020,683,00015,303,00015,144,00013,330,3038,977,3138,734,7178,460,9997,403,7337,199,6636,783,1156,602,9425,895,1946,028,5155,405,5945,238,2364,353,0534,128,2733,911,1333,902,5483,501,1413,283,7663,175,2472,866,6812,830,8892,717,9042,791,4821,731,5271,797,0231,675,9961,754,7061,692,8861,772,1281,417,8661,459,5761,564,4321,672,9012,052,8182,202,5632,481,6012,458,2461,954,9292,081,3652,221,534000
   > Total Current Assets 
0
0
0
2,156,252
2,020,900
1,888,044
2,396,968
2,419,367
2,143,582
1,997,619
1,618,999
1,516,800
1,415,382
1,375,702
1,729,127
1,653,810
1,719,993
1,643,928
1,764,986
1,692,983
2,750,574
2,678,556
2,727,889
2,766,354
3,032,633
3,054,614
3,279,154
3,667,889
3,683,032
3,907,255
4,142,062
4,897,639
5,076,189
5,718,727
5,565,746
6,059,427
6,221,203
6,675,573
6,571,981
7,433,025
7,535,525
7,810,864
12,256,302
13,961,000
14,090,000
19,141,000
19,504,000
18,791,000
19,937,000
20,304,000
21,954,000
22,736,000
23,175,000
25,491,000
28,739,000
28,377,000
28,231,000
29,749,000
33,027,000
33,139,000
33,139,00033,027,00029,749,00028,231,00028,377,00028,739,00025,491,00023,175,00022,736,00021,954,00020,304,00019,937,00018,791,00019,504,00019,141,00014,090,00013,961,00012,256,3027,810,8647,535,5257,433,0256,571,9816,675,5736,221,2036,059,4275,565,7465,718,7275,076,1894,897,6394,142,0623,907,2553,683,0323,667,8893,279,1543,054,6143,032,6332,766,3542,727,8892,678,5562,750,5741,692,9831,764,9861,643,9281,719,9931,653,8101,729,1271,375,7021,415,3821,516,8001,618,9991,997,6192,143,5822,419,3672,396,9681,888,0442,020,9002,156,252000
       Cash And Cash Equivalents 
0
0
0
460,738
268,139
435,242
414,435
100,950
101,392
92,534
164,991
65,197
112,250
126,778
410,056
66,992
126,530
182,559
181,346
168,135
670,651
393,402
271,796
359,087
328,538
367,182
584,263
873,986
634,914
641,700
796,665
307,023
764,415
1,031,721
1,086,471
1,347,545
956,775
1,087,165
896,074
532,907
1,176,813
582,863
4,643,035
3,552,000
5,543,000
6,605,000
8,892,000
7,260,000
7,892,000
9,477,000
8,729,000
8,957,000
9,071,000
9,816,000
10,377,000
9,893,000
12,288,000
10,874,000
14,273,000
14,867,000
14,867,00014,273,00010,874,00012,288,0009,893,00010,377,0009,816,0009,071,0008,957,0008,729,0009,477,0007,892,0007,260,0008,892,0006,605,0005,543,0003,552,0004,643,035582,8631,176,813532,907896,0741,087,165956,7751,347,5451,086,4711,031,721764,415307,023796,665641,700634,914873,986584,263367,182328,538359,087271,796393,402670,651168,135181,346182,559126,53066,992410,056126,778112,25065,197164,99192,534101,392100,950414,435435,242268,139460,738000
       Short-term Investments 
0
0
0
816,910
804,683
485,003
1,272,450
1,548,309
1,343,174
1,208,266
1,048,177
1,035,422
906,011
817,394
768,554
1,436,757
1,362,841
1,364,148
1,469,913
1,388,844
1,859,115
2,190,776
2,366,712
2,301,428
2,616,596
2,590,595
2,621,343
2,619,243
2,855,608
3,120,422
3,145,808
3,614,942
3,986,210
4,183,038
4,097,431
4,075,192
4,744,397
4,983,770
4,999,349
5,573,187
5,653,459
6,368,090
6,473,814
7,419,000
7,417,000
6,177,000
8,577,000
8,819,000
10,191,000
8,398,000
10,014,000
10,381,000
10,917,000
11,799,000
13,411,000
12,431,000
12,256,000
14,010,000
13,252,000
13,268,000
13,268,00013,252,00014,010,00012,256,00012,431,00013,411,00011,799,00010,917,00010,381,00010,014,0008,398,00010,191,0008,819,0008,577,0006,177,0007,417,0007,419,0006,473,8146,368,0905,653,4595,573,1874,999,3494,983,7704,744,3974,075,1924,097,4314,183,0383,986,2103,614,9423,145,8083,120,4222,855,6082,619,2432,621,3432,590,5952,616,5962,301,4282,366,7122,190,7761,859,1151,388,8441,469,9131,364,1481,362,8411,436,757768,554817,394906,0111,035,4221,048,1771,208,2661,343,1741,548,3091,272,450485,003804,683816,910000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
136,692
165,982
97,221
113,727
136,004
220,808
94,378
89,381
105,839
87,499
96,837
73,548
174,660
192,510
145,133
199,589
975,674
325,564
503,968
381,844
636,690
520,031
604,638
676,558
1,326,931
705,253
859,911
1,139,453
2,990,000
1,130,000
6,359,000
2,035,000
2,712,000
1,854,000
2,429,000
3,211,000
3,398,000
3,187,000
3,876,000
4,951,000
6,053,000
3,687,000
4,814,000
5,432,000
4,947,000
4,947,0005,432,0004,814,0003,687,0006,053,0004,951,0003,876,0003,187,0003,398,0003,211,0002,429,0001,854,0002,712,0002,035,0006,359,0001,130,0002,990,0001,139,453859,911705,2531,326,931676,558604,638520,031636,690381,844503,968325,564975,674199,589145,133192,510174,66073,54896,83787,499105,83989,38194,378220,808136,004113,72797,221165,982136,692000000000000000
       Other Current Assets 
0
0
0
878,604
948,078
967,799
710,083
770,108
699,016
696,819
405,831
416,181
397,121
431,530
550,517
13,369
64,640
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,398,000
0
0
0
0
0
0
0
0
0
0
0
143,000
488,000
124,000
0
0
00124,000488,000143,0000000000000010,398,0000000000000000000000000000064,64013,369550,517431,530397,121416,181405,831696,819699,016770,108710,083967,799948,078878,604000
   > Long-term Assets 
0
0
0
65,282
60,465
66,885
61,278
62,234
58,981
55,199
53,902
47,632
44,194
42,164
43,001
39,076
34,713
32,068
32,037
38,544
40,908
39,348
103,000
100,327
142,614
229,152
221,987
234,659
228,101
221,018
210,991
340,597
329,405
309,788
329,448
543,515
561,912
524,090
831,752
1,027,974
1,199,192
1,166,449
1,074,001
1,183,000
1,213,000
1,542,000
2,018,000
2,352,000
2,273,000
2,179,000
2,031,000
1,891,000
1,739,000
1,985,000
1,947,000
1,901,000
2,163,000
2,229,000
2,211,000
2,150,000
2,150,0002,211,0002,229,0002,163,0001,901,0001,947,0001,985,0001,739,0001,891,0002,031,0002,179,0002,273,0002,352,0002,018,0001,542,0001,213,0001,183,0001,074,0011,166,4491,199,1921,027,974831,752524,090561,912543,515329,448309,788329,405340,597210,991221,018228,101234,659221,987229,152142,614100,327103,00039,34840,90838,54432,03732,06834,71339,07643,00142,16444,19447,63253,90255,19958,98162,23461,27866,88560,46565,282000
       Property Plant Equipment 
0
0
0
60,180
55,594
53,528
49,371
41,430
38,320
36,249
33,869
32,395
29,732
27,799
25,079
25,960
23,190
22,422
19,873
22,662
22,167
23,822
24,409
25,684
23,810
25,482
25,624
28,812
30,521
31,085
30,215
32,194
33,491
66,725
90,175
113,415
139,610
147,026
152,681
161,545
367,857
366,927
371,549
414,000
491,000
726,000
730,000
736,000
842,000
919,000
957,000
975,000
975,000
1,238,000
1,289,000
1,322,000
1,596,000
1,634,000
1,651,000
1,641,000
1,641,0001,651,0001,634,0001,596,0001,322,0001,289,0001,238,000975,000975,000957,000919,000842,000736,000730,000726,000491,000414,000371,549366,927367,857161,545152,681147,026139,610113,41590,17566,72533,49132,19430,21531,08530,52128,81225,62425,48223,81025,68424,40923,82222,16722,66219,87322,42223,19025,96025,07927,79929,73232,39533,86936,24938,32041,43049,37153,52855,59460,180000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
149,000
149,000
152,000
647,000
1,081,000
905,000
753,000
587,000
371,000
239,000
201,000
155,000
133,000
140,000
183,000
156,000
134,000
134,000156,000183,000140,000133,000155,000201,000239,000371,000587,000753,000905,0001,081,000647,000152,000149,000149,0000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,541
0
0
0
62,530
0
0
0
192,642
0
0
0
181,895
0
0
0
124,395
0
178,993
75,521
470,359
445,904
421,429
419,632
470,000
442,000
0
0
338,000
0
0
0
254,000
0
216,000
200,000
146,000
132,000
129,000
115,000
0
0115,000129,000132,000146,000200,000216,0000254,000000338,00000442,000470,000419,632421,429445,904470,35975,521178,9930124,395000181,895000192,64200062,5300002,5410000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
259,861
29,923
1,435
374,257
378,093
282,820
150,000
131,000
251,000
256,000
197,000
209,000
210,000
212,000
291,000
291,000
330,000
303,000
300,000
0
283,000
289,000
0
0289,000283,0000300,000303,000330,000291,000291,000212,000210,000209,000197,000256,000251,000131,000150,000282,820378,093374,2571,43529,923259,8610000000000000000000000000000000000000
> Total Liabilities 
0
0
0
924,342
867,415
750,681
1,311,695
1,401,534
1,244,268
1,172,310
1,138,118
1,078,014
1,032,451
1,002,987
1,403,774
1,309,699
1,266,551
1,179,894
1,283,670
1,072,004
1,027,369
967,492
897,328
833,742
587,099
514,145
461,961
415,828
389,880
379,652
418,941
411,540
399,375
589,161
428,341
330,750
263,012
338,438
324,564
446,639
607,555
690,804
815,672
1,096,000
905,000
2,812,000
3,045,000
2,022,000
2,115,000
2,231,000
2,700,000
2,431,000
2,195,000
2,994,000
4,029,000
2,837,000
3,204,000
3,223,000
4,126,000
3,679,000
3,679,0004,126,0003,223,0003,204,0002,837,0004,029,0002,994,0002,195,0002,431,0002,700,0002,231,0002,115,0002,022,0003,045,0002,812,000905,0001,096,000815,672690,804607,555446,639324,564338,438263,012330,750428,341589,161399,375411,540418,941379,652389,880415,828461,961514,145587,099833,742897,328967,4921,027,3691,072,0041,283,6701,179,8941,266,5511,309,6991,403,7741,002,9871,032,4511,078,0141,138,1181,172,3101,244,2681,401,5341,311,695750,681867,415924,342000
   > Total Current Liabilities 
0
0
0
894,338
840,830
707,884
1,274,196
1,324,611
1,174,806
1,107,108
1,074,095
976,728
935,589
927,769
1,326,900
1,183,650
1,143,394
1,056,584
1,160,827
907,502
861,563
795,522
719,395
655,968
585,607
512,712
460,528
414,395
388,447
378,219
418,941
411,540
399,375
589,161
426,792
327,121
259,295
334,864
321,132
443,349
435,704
524,558
654,766
938,000
740,000
2,009,000
2,258,000
1,253,000
1,293,000
1,351,000
1,830,000
1,568,000
1,339,000
1,944,000
2,988,000
1,823,000
1,955,000
1,993,000
2,902,000
2,484,000
2,484,0002,902,0001,993,0001,955,0001,823,0002,988,0001,944,0001,339,0001,568,0001,830,0001,351,0001,293,0001,253,0002,258,0002,009,000740,000938,000654,766524,558435,704443,349321,132334,864259,295327,121426,792589,161399,375411,540418,941378,219388,447414,395460,528512,712585,607655,968719,395795,522861,563907,5021,160,8271,056,5841,143,3941,183,6501,326,900927,769935,589976,7281,074,0951,107,1081,174,8061,324,6111,274,196707,884840,830894,338000
       Short-term Debt 
0
0
0
7,004
6,652
6,443
6,268
121,871
6,099
6,198
7,388
5,789
5,575
4,910
4,540
3,768
3,807
4,032
156,291
2,129
238
237
237
237
237
237
178
118
59
0
0
61,612
0
0
0
0
0
0
0
0
31,155
31,237
30,997
26,000
26,000
43,000
42,000
42,000
52,000
59,000
63,000
62,000
60,000
80,000
79,000
74,000
89,000
82,000
83,000
90,000
90,00083,00082,00089,00074,00079,00080,00060,00062,00063,00059,00052,00042,00042,00043,00026,00026,00030,99731,23731,1550000000061,61200591181782372372372372372382,129156,2914,0323,8073,7684,5404,9105,5755,7897,3886,1986,099121,8716,2686,4436,6527,004000
       Accounts payable 
0
0
0
44,808
39,016
33,522
34,460
32,761
25,891
21,307
29,754
33,510
16,156
17,161
21,910
79,805
107,499
0
0
0
0
0
0
0
0
0
0
31,989
0
0
0
22,271
0
0
0
0
0
0
0
0
0
0
0
0
0
1,085,000
1,226,000
0
70,000
186,000
469,000
350,000
0
1,575,000
1,922,000
1,716,000
1,833,000
1,878,000
2,341,000
2,307,000
2,307,0002,341,0001,878,0001,833,0001,716,0001,922,0001,575,0000350,000469,000186,00070,00001,226,0001,085,000000000000000022,27100031,9890000000000107,49979,80521,91017,16116,15633,51029,75421,30725,89132,76134,46033,52239,01644,808000
       Other Current Liabilities 
0
0
0
344,245
401,420
327,665
130,389
68,102
97,209
92,887
104,451
63,621
96,088
105,865
101,604
9,712
12,319
107,808
130,624
87,881
114,390
115,040
101,805
105,488
107,282
106,543
103,054
99,580
128,307
135,955
167,087
99,507
194,928
407,652
267,118
176,473
259,295
334,864
321,132
443,349
404,549
493,321
623,769
912,000
714,000
855,000
964,000
1,185,000
1,145,000
1,080,000
1,272,000
1,130,000
1,253,000
263,000
954,000
1,716,000
1,833,000
1,878,000
445,000
54,000
54,000445,0001,878,0001,833,0001,716,000954,000263,0001,253,0001,130,0001,272,0001,080,0001,145,0001,185,000964,000855,000714,000912,000623,769493,321404,549443,349321,132334,864259,295176,473267,118407,652194,92899,507167,087135,955128,30799,580103,054106,543107,282105,488101,805115,040114,39087,881130,624107,80812,3199,712101,604105,86596,08863,621104,45192,88797,20968,102130,389327,665401,420344,245000
   > Long-term Liabilities 
0
0
0
30,004
26,585
42,797
37,499
76,923
69,462
65,202
64,023
101,286
96,862
75,218
76,874
126,049
123,157
123,310
122,843
164,502
165,806
171,970
177,933
177,774
1,492
1,433
1,433
1,433
1,433
1,433
0
0
0
0
1,549
3,629
3,717
3,574
3,432
3,290
171,851
166,246
160,906
158,000
165,000
803,000
787,000
769,000
822,000
880,000
870,000
863,000
856,000
1,050,000
1,041,000
1,014,000
1,249,000
1,230,000
1,224,000
1,195,000
1,195,0001,224,0001,230,0001,249,0001,014,0001,041,0001,050,000856,000863,000870,000880,000822,000769,000787,000803,000165,000158,000160,906166,246171,8513,2903,4323,5743,7173,6291,54900001,4331,4331,4331,4331,4331,492177,774177,933171,970165,806164,502122,843123,310123,157126,04976,87475,21896,862101,28664,02365,20269,46276,92337,49942,79726,58530,004000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
168,274
162,811
157,614
155,000
148,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000148,000155,000157,614162,811168,2740000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,160
533
12
3,577
3,435
3,292
3,000
17,000
490,000
492,000
492,000
496,000
496,000
496,000
500,000
500,000
496,000
491,000
491,000
0
509,000
514,000
0
0514,000509,0000491,000491,000496,000500,000500,000496,000496,000496,000492,000492,000490,00017,0003,0003,2923,4353,577125334,1600000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
1,297,192
1,213,950
1,204,248
1,146,551
1,080,067
958,295
880,508
534,783
486,418
427,125
414,879
368,354
383,187
488,155
496,102
513,353
659,523
1,764,113
1,750,412
1,933,561
2,032,939
2,588,148
2,769,621
3,039,180
3,486,720
3,521,253
3,748,621
3,934,112
4,826,696
5,006,219
5,439,354
5,466,853
6,272,192
6,520,103
6,861,225
7,079,169
8,014,360
8,127,162
8,286,509
12,514,631
14,048,000
14,398,000
17,871,000
18,477,000
19,121,000
20,095,000
20,252,000
21,285,000
22,196,000
22,719,000
24,482,000
26,657,000
27,441,000
27,190,000
28,755,000
31,112,000
31,610,000
31,610,00031,112,00028,755,00027,190,00027,441,00026,657,00024,482,00022,719,00022,196,00021,285,00020,252,00020,095,00019,121,00018,477,00017,871,00014,398,00014,048,00012,514,6318,286,5098,127,1628,014,3607,079,1696,861,2256,520,1036,272,1925,466,8535,439,3545,006,2194,826,6963,934,1123,748,6213,521,2533,486,7203,039,1802,769,6212,588,1482,032,9391,933,5611,750,4121,764,113659,523513,353496,102488,155383,187368,354414,879427,125486,418534,783880,508958,2951,080,0671,146,5511,204,2481,213,9501,297,192000
   Common Stock
0
0
0
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
44,907
50,308
50,713
51,053
51,211
51,756
56,629
56,687
56,821
56,967
58,134
58,717
59,322
59,531
59,678
59,834
60,248
60,350
60,735
61,118
61,163
61,186
61,251
61,437
61,490
61,498
61,524
61,690
64,989
65,000
65,000
65,000
65,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,000
66,00066,00066,00066,00066,00066,00066,00066,00066,00066,00066,00066,00066,00065,00065,00065,00065,00064,98961,69061,52461,49861,49061,43761,25161,18661,16361,11860,73560,35060,24859,83459,67859,53159,32258,71758,13456,96756,82156,68756,62951,75651,21151,05350,71350,30844,90744,90744,90744,90744,90744,90744,90744,90744,90744,90744,90744,907000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-136,762
0
0
0
-147,820
0
0
0
80,322
80,305
77,731
75,778
77,180
77,224
77,731
81,322
84,101
95,824
91,778
91,715
94,476
90,109
92,544
92,163
102,883
102,790
103,270
95,071
82,080
77,189
87,524
88,588
91,707
95,674
95,710
100,386
98,000
107,000
98,000
74,000
54,000
95,000
82,000
84,000
81,000
97,000
110,000
151,000
98,000
117,000
112,000
142,000
60,000
60,000142,000112,000117,00098,000151,000110,00097,00081,00084,00082,00095,00054,00074,00098,000107,00098,000100,38695,71095,67491,70788,58887,52477,18982,08095,071103,270102,790102,88392,16392,54490,10994,47691,71591,77895,82484,10181,32277,73177,22477,18075,77877,73180,30580,322000-147,820000-136,7620000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
190,081
8,063,977
8,097,093
11,738,022
11,755,000
11,796,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000011,796,00011,755,00011,738,0228,097,0938,063,977190,081000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
5,427,155
5,458,304
5,505,794
5,457,875
5,601,776
5,448,504
5,444,565
5,456,261
5,595,510
5,453,737
5,440,342
5,447,314
5,733,855
5,762,884
5,796,100
5,807,386
5,887,957
6,882,289
6,887,217
6,900,143
6,920,226
7,236,241
7,396,029
7,516,327
7,560,991
7,599,288
7,642,689
7,744,089
7,769,577
7,872,470
7,962,568
7,976,996
7,983,652
8,001,919
8,044,066
8,056,912
8,058,614
8,063,977
8,097,093
11,738,022
11,755,000
11,796,000
11,826,000
11,875,000
11,894,000
11,914,000
11,940,000
11,996,000
12,029,000
12,044,000
12,063,000
12,141,000
12,309,000
12,341,000
12,412,000
12,452,000
12,461,000
12,461,00012,452,00012,412,00012,341,00012,309,00012,141,00012,063,00012,044,00012,029,00011,996,00011,940,00011,914,00011,894,00011,875,00011,826,00011,796,00011,755,00011,738,0228,097,0938,063,9778,058,6148,056,9128,044,0668,001,9197,983,6527,976,9967,962,5687,872,4707,769,5777,744,0897,642,6897,599,2887,560,9917,516,3277,396,0297,236,2416,920,2266,900,1436,887,2176,882,2895,887,9575,807,3865,796,1005,762,8845,733,8555,447,3145,440,3425,453,7375,595,5105,456,2615,444,5655,448,5045,601,7765,457,8755,505,7945,458,3045,427,155000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue16,474,000
Cost of Revenue-553,000
Gross Profit15,921,00015,921,000
 
Operating Income (+$)
Gross Profit15,921,000
Operating Expense-10,600,000
Operating Income5,321,0005,321,000
 
Operating Expense (+$)
Research Development7,435,000
Selling General Administrative3,297,000
Selling And Marketing Expenses0
Operating Expense10,600,00010,732,000
 
Net Interest Income (+$)
Interest Income939,000
Interest Expense-27,000
Other Finance Cost-0
Net Interest Income912,000
 
Pretax Income (+$)
Operating Income5,321,000
Net Interest Income912,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)5,637,0005,005,000
EBIT - interestExpense = 5,294,000
5,637,000
4,379,000
Interest Expense27,000
Earnings Before Interest and Taxes (EBIT)5,321,0005,664,000
Earnings Before Interest and Taxes (EBITDA)5,648,000
 
After tax Income (+$)
Income Before Tax5,637,000
Tax Provision-1,285,000
Net Income From Continuing Ops4,352,0004,352,000
Net Income4,352,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses11,153,000
Total Other Income/Expenses Net316,000-912,000
 

Technical Analysis of Genmab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genmab. The general trend of Genmab is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genmab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Genmab AS.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 29.17 < 31.02 < 31.88.

The bearish price targets are: 27.51 > 26.32 > 26.19.

Tweet this
Genmab AS Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Genmab AS. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Genmab AS Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Genmab AS. The current macd is -0.23452134.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Genmab price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genmab. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genmab price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Genmab AS Daily Moving Average Convergence/Divergence (MACD) ChartGenmab AS Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Genmab AS. The current adx is 12.30.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Genmab shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Genmab AS Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Genmab AS. The current sar is 29.97.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Genmab AS Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Genmab AS. The current rsi is 44.86. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Genmab AS Daily Relative Strength Index (RSI) ChartGenmab AS Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Genmab AS. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genmab price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Genmab AS Daily Stochastic Oscillator ChartGenmab AS Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Genmab AS. The current cci is -90.79101338.

Genmab AS Daily Commodity Channel Index (CCI) ChartGenmab AS Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Genmab AS. The current cmo is -13.57035985.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Genmab AS Daily Chande Momentum Oscillator (CMO) ChartGenmab AS Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Genmab AS. The current willr is -69.22937689.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genmab is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Genmab AS Daily Williams %R ChartGenmab AS Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Genmab AS.

Genmab AS Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Genmab AS. The current atr is 0.62114788.

Genmab AS Daily Average True Range (ATR) ChartGenmab AS Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Genmab AS. The current obv is -6,512,977.

Genmab AS Daily On-Balance Volume (OBV) ChartGenmab AS Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Genmab AS. The current mfi is 51.58.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Genmab AS Daily Money Flow Index (MFI) ChartGenmab AS Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Genmab AS.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Genmab AS Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Genmab AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.860
Ma 20Greater thanMa 5029.627
Ma 50Greater thanMa 10029.339
Ma 100Greater thanMa 20029.874
OpenGreater thanClose28.850
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genmab with someone you think should read this too:
  • Are you bullish or bearish on Genmab? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genmab? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Genmab AS

I send you an email if I find something interesting about Genmab AS.


Comments

How you think about this?

Leave a comment

Stay informed about Genmab AS.

Receive notifications about Genmab AS in your mailbox!